Blog
RSS FeedPosted by Michael Wonder on 23 Jan 2017
NICE seeks positive future with life sciences industry
20 January 2017 - NICE has set out its position on its complex but positive relationship with the life sciences industry. ...
Posted by Michael Wonder on 19 Jan 2017
Drug cost-saving plans may hit patients
19 January 2017 - Patients in England may face delays getting new drugs or go without them if NHS bosses ...
Posted by Michael Wonder on 16 Jan 2017
Breast cancer patients' distress at withdrawal of Kadcyla
16 January 2017 - Terminal breast cancer patients have spoken of their distress after learning that a life-extending drug they ...
Posted by Michael Wonder on 16 Jan 2017
Pause on NICE’s cost recovery plans
16 January 2017 - Plans for NICE to recover the costs of its appraisals of drugs, medical devices and diagnostics, ...
Posted by Michael Wonder on 12 Jan 2017
NICE approves kidney cancer drug for NHS use
12 January 2017 - Patients with advanced kidney cancer will have routine NHS access to the drug everolimus following recommendations by ...
Posted by Michael Wonder on 11 Jan 2017
NICE publishes final guidance on the use of Keytruda for non-small-cell lung cancer
11 January 2017 - The guidance relates to the use of Keytruda (pembrolizumab) for treating PD-L1-positive non-small-cell lung cancer in adults ...
Posted by Michael Wonder on 09 Jan 2017
NICE takes key role in new European project for faster access to Alzheimer’s disease drugs
6 January 2017 - Patients’ priorities will be brought to the fore in new Alzheimer’s project. ...
Posted by Michael Wonder on 06 Jan 2017
Trastuzumab emtansine and cost-based decision making
7 January 2017 - On 29 December 2016, the NICE in the UK invited comments on their draft guidance for use ...
Posted by Michael Wonder on 05 Jan 2017
NICE publishes second appraisal consultation for certolizumab pegol and secukinumab
5 January 2017 - NICE is appraising certolizumab pegol and secukinumab for psoriatic arthritis. ...
Posted by Michael Wonder on 05 Jan 2017
Dying mum begs NHS to keep cancer drug free so she can live to see son go to school
5 January 2017 - Dying Bonnie Fox, 39, was diagnosed with secondary cancer in July 2015 only four months after her ...
Posted by Michael Wonder on 03 Jan 2017
Amicus Therapeutics set for share of Fabry market after NICE approval
3 January 2017 - England and Wales’ cost effectiveness watchdog NICE has given a final recommendation to a new treatment ...
Posted by Michael Wonder on 03 Jan 2017
The NICE year in review
3 January 2017 - NICE has reflected on some of the news over the past twelve months. ...
Posted by Michael Wonder on 03 Jan 2017
NICE says liver cancer treatment to stay within the Cancer Drugs Fund, but not recommended for routine NHS use
30 December 2016 - The drug, sorafenib tosylate (Nexavar), which is used for treating advanced hepatocellular carcinoma, is not value for ...
Posted by Michael Wonder on 31 Dec 2016
Breast cancer drug rejected for NHS use on cost-benefit grounds
29 December 2016 - Charities angered by guidance on Kadcyla, which costs £90,000 per year per patient and gives extra nine ...
Posted by Michael Wonder on 30 Dec 2016
AstraZeneca chief says NHS drug approval process hurts patients
29 December 2016 - Protracted negotiations deny access to life-saving treatments, says Pascal Soriot. ...